TY - JOUR
AU - 
AB - ORIGINAL STUDIES Reactogenicity of Tetanus, Diphtheria, 5-Component Acellular Pertussis Vaccine Administered as a Sixth Consecutive Acellular Pertussis Vaccine Dose to Adolescents Johannes G. Liese, MD, MSc,* Nikolaus Rieber, MD,† Thomas Malzer, MD,‡ Marion Ocak, Diplom,§ David R. Johnson, MD, MPH,¶ and Michael D. Decker, MD, MPH,¶
 for the Munich Vaccine Study Group cellular vaccines against Bordetella pertussis are administered Background: Safety of a sixth consecutive dose of acellular pertussis Ato infants (doses 1–3) and toddlers (dose 4) to protect against vaccine in adolescents was assessed in a 2-armed, randomized study. pertussis and feature a more favorable tolerability profile than 1,2 Methods: Adolescents who had received 5 doses of acellular pertussis whole-cell pertussis vaccines. Clinical data support the use of vaccine combined with diphtheria and tetanus toxoids (6-dose group) acellular pertussis vaccines as a fifth dose of pertussis vaccine received 1 dose of reduced 5-component acellular pertussis vaccine com- before the age of 6 years to ensure ongoing disease protection; bined with tetanus toxoid and reduced diphtheria toxoid (Tdap). Adoles- however, reactogenicity with repeated doses of acellular pertussis 1,3–5 6 cents who had received a primary series of 3 doses of whole-cell pertussis vaccines is a concern. Pichichero et al 
TI - Clostridium Difficile
JF - Pediatric Infectious Disease Journal
DO - 10.1097/INF.0b013e3181fcdb55
DA - 2010-12-01
UR - https://www.deepdyve.com/lp/wolters-kluwer-health/clostridium-difficile-la0cMpod36
SP - 1071
EP - 1071
VL - 29
IS - 12
DP - DeepDyve
ER -